Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure

To develop a valid, disease-specific, patient-reported outcome (PRO) measure for adolescents and adults with Friedreich ataxia (FA) for use in therapeutic trials. We conducted semistructured qualitative interviews and a national cross-sectional study of individuals with FA to determine the most prev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology. Clinical practice 2023-10, Vol.13 (5), p.e200180
Hauptverfasser: Seabury, Jamison, Rosero, Spencer, Varma, Anika, Weinstein, Jennifer, Engebrecht, Charlotte, Dilek, Nuran, Heatwole, John, Alexandrou, Danae, Cohen, Brittany, Larkindale, Jane, Lynch, David R, Park, Courtney, Subramony, Sub H, Wagner, Ellen, Walther, Susan, Wells, McKenzie, Zizzi, Christine, Heatwole, Chad
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page e200180
container_title Neurology. Clinical practice
container_volume 13
creator Seabury, Jamison
Rosero, Spencer
Varma, Anika
Weinstein, Jennifer
Engebrecht, Charlotte
Dilek, Nuran
Heatwole, John
Alexandrou, Danae
Cohen, Brittany
Larkindale, Jane
Lynch, David R
Park, Courtney
Subramony, Sub H
Wagner, Ellen
Walther, Susan
Wells, McKenzie
Zizzi, Christine
Heatwole, Chad
description To develop a valid, disease-specific, patient-reported outcome (PRO) measure for adolescents and adults with Friedreich ataxia (FA) for use in therapeutic trials. We conducted semistructured qualitative interviews and a national cross-sectional study of individuals with FA to determine the most prevalent and burdensome symptoms and symptomatic themes to this population. These symptoms and symptomatic themes were included as questions in the first version of the Friedreich's Ataxia-Health Index (FA-HI). We subsequently used factor analysis, beta interviews with 17 individuals with FA, and test-retest reliability assessments with 20 individuals with FA to evaluate, refine, and optimize the FA-HI. Finally, we determined the capability of the FA-HI to differentiate between subgroups of FA participants with varying levels of disease severity. Participants with FA identified 18 symptomatic themes of importance to be included as subscales in the FA-HI. The FA-HI demonstrates high internal consistency and test-retest reliability, and it was identified by participants as highly relevant, comprehensive, and easy to complete. FA-HI total and subscale scores statistically differentiated between subgroups of participants with varying levels of disease burden. Initial evaluation of the FA-HI supports its validity and reliability as a PRO for assessing how individuals with FA feel and function.
doi_str_mv 10.1212/CPJ.0000000000200180
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10462051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2858994115</sourcerecordid><originalsourceid>FETCH-LOGICAL-c227t-c00aa4f05d88a258cbf52a0aa7f06ced5008822558ae3e7eb0b8c1d335c468d13</originalsourceid><addsrcrecordid>eNpdkU9v1DAQxS0EolXpN0DIN7ikjO046-WCqi2lRYVW_Ltas_aENUri1E6q9tvjVdsV4MtYnt97Hs1j7KWAIyGFfLu6-nQEuyMBhIEnbF-KRlWwVOrp470GuccOc_695RoQSi6fsz21aOoG6maf3Z2mQD5RcJvXmR9PeBuwOiPspg0_HzzdvuMndENdHHsaJo6D5z-xCx6nEAceW478Syx9fhIyYabq20gutMHxq4IUSfWVxpgm8vxynlzsiX8u3JzoBXvWYpfp8KEesB-nH76vzqqLy4_nq-OLykm5mCoHgFi3oL0xKLVx61ZLLG-LFhpHXgMYI6XWBknRgtawNk54pbSrG-OFOmDv733Hed2Td2WmhJ0dU-gx3dmIwf7bGcLG_oo3VpQFSdBbhzcPDilez5Qn24fsqOtwoDhnK402y2UthC5ofY-6FHNO1O7-EWC3ydmSnP0_uSJ79feMO9FjTuoP792VZQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2858994115</pqid></control><display><type>article</type><title>Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure</title><source>Journals@Ovid Complete</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Seabury, Jamison ; Rosero, Spencer ; Varma, Anika ; Weinstein, Jennifer ; Engebrecht, Charlotte ; Dilek, Nuran ; Heatwole, John ; Alexandrou, Danae ; Cohen, Brittany ; Larkindale, Jane ; Lynch, David R ; Park, Courtney ; Subramony, Sub H ; Wagner, Ellen ; Walther, Susan ; Wells, McKenzie ; Zizzi, Christine ; Heatwole, Chad</creator><creatorcontrib>Seabury, Jamison ; Rosero, Spencer ; Varma, Anika ; Weinstein, Jennifer ; Engebrecht, Charlotte ; Dilek, Nuran ; Heatwole, John ; Alexandrou, Danae ; Cohen, Brittany ; Larkindale, Jane ; Lynch, David R ; Park, Courtney ; Subramony, Sub H ; Wagner, Ellen ; Walther, Susan ; Wells, McKenzie ; Zizzi, Christine ; Heatwole, Chad</creatorcontrib><description>To develop a valid, disease-specific, patient-reported outcome (PRO) measure for adolescents and adults with Friedreich ataxia (FA) for use in therapeutic trials. We conducted semistructured qualitative interviews and a national cross-sectional study of individuals with FA to determine the most prevalent and burdensome symptoms and symptomatic themes to this population. These symptoms and symptomatic themes were included as questions in the first version of the Friedreich's Ataxia-Health Index (FA-HI). We subsequently used factor analysis, beta interviews with 17 individuals with FA, and test-retest reliability assessments with 20 individuals with FA to evaluate, refine, and optimize the FA-HI. Finally, we determined the capability of the FA-HI to differentiate between subgroups of FA participants with varying levels of disease severity. Participants with FA identified 18 symptomatic themes of importance to be included as subscales in the FA-HI. The FA-HI demonstrates high internal consistency and test-retest reliability, and it was identified by participants as highly relevant, comprehensive, and easy to complete. FA-HI total and subscale scores statistically differentiated between subgroups of participants with varying levels of disease burden. Initial evaluation of the FA-HI supports its validity and reliability as a PRO for assessing how individuals with FA feel and function.</description><identifier>ISSN: 2163-0402</identifier><identifier>EISSN: 2163-0933</identifier><identifier>DOI: 10.1212/CPJ.0000000000200180</identifier><identifier>PMID: 37646046</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><ispartof>Neurology. Clinical practice, 2023-10, Vol.13 (5), p.e200180</ispartof><rights>2023 American Academy of Neurology.</rights><rights>2023 American Academy of Neurology 2023 American Academy of Neurology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c227t-c00aa4f05d88a258cbf52a0aa7f06ced5008822558ae3e7eb0b8c1d335c468d13</cites><orcidid>0000-0001-7168-214X ; 0000-0002-8052-9240</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462051/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462051/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37646046$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seabury, Jamison</creatorcontrib><creatorcontrib>Rosero, Spencer</creatorcontrib><creatorcontrib>Varma, Anika</creatorcontrib><creatorcontrib>Weinstein, Jennifer</creatorcontrib><creatorcontrib>Engebrecht, Charlotte</creatorcontrib><creatorcontrib>Dilek, Nuran</creatorcontrib><creatorcontrib>Heatwole, John</creatorcontrib><creatorcontrib>Alexandrou, Danae</creatorcontrib><creatorcontrib>Cohen, Brittany</creatorcontrib><creatorcontrib>Larkindale, Jane</creatorcontrib><creatorcontrib>Lynch, David R</creatorcontrib><creatorcontrib>Park, Courtney</creatorcontrib><creatorcontrib>Subramony, Sub H</creatorcontrib><creatorcontrib>Wagner, Ellen</creatorcontrib><creatorcontrib>Walther, Susan</creatorcontrib><creatorcontrib>Wells, McKenzie</creatorcontrib><creatorcontrib>Zizzi, Christine</creatorcontrib><creatorcontrib>Heatwole, Chad</creatorcontrib><title>Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure</title><title>Neurology. Clinical practice</title><addtitle>Neurol Clin Pract</addtitle><description>To develop a valid, disease-specific, patient-reported outcome (PRO) measure for adolescents and adults with Friedreich ataxia (FA) for use in therapeutic trials. We conducted semistructured qualitative interviews and a national cross-sectional study of individuals with FA to determine the most prevalent and burdensome symptoms and symptomatic themes to this population. These symptoms and symptomatic themes were included as questions in the first version of the Friedreich's Ataxia-Health Index (FA-HI). We subsequently used factor analysis, beta interviews with 17 individuals with FA, and test-retest reliability assessments with 20 individuals with FA to evaluate, refine, and optimize the FA-HI. Finally, we determined the capability of the FA-HI to differentiate between subgroups of FA participants with varying levels of disease severity. Participants with FA identified 18 symptomatic themes of importance to be included as subscales in the FA-HI. The FA-HI demonstrates high internal consistency and test-retest reliability, and it was identified by participants as highly relevant, comprehensive, and easy to complete. FA-HI total and subscale scores statistically differentiated between subgroups of participants with varying levels of disease burden. Initial evaluation of the FA-HI supports its validity and reliability as a PRO for assessing how individuals with FA feel and function.</description><issn>2163-0402</issn><issn>2163-0933</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdkU9v1DAQxS0EolXpN0DIN7ikjO046-WCqi2lRYVW_Ltas_aENUri1E6q9tvjVdsV4MtYnt97Hs1j7KWAIyGFfLu6-nQEuyMBhIEnbF-KRlWwVOrp470GuccOc_695RoQSi6fsz21aOoG6maf3Z2mQD5RcJvXmR9PeBuwOiPspg0_HzzdvuMndENdHHsaJo6D5z-xCx6nEAceW478Syx9fhIyYabq20gutMHxq4IUSfWVxpgm8vxynlzsiX8u3JzoBXvWYpfp8KEesB-nH76vzqqLy4_nq-OLykm5mCoHgFi3oL0xKLVx61ZLLG-LFhpHXgMYI6XWBknRgtawNk54pbSrG-OFOmDv733Hed2Td2WmhJ0dU-gx3dmIwf7bGcLG_oo3VpQFSdBbhzcPDilez5Qn24fsqOtwoDhnK402y2UthC5ofY-6FHNO1O7-EWC3ydmSnP0_uSJ79feMO9FjTuoP792VZQ</recordid><startdate>202310</startdate><enddate>202310</enddate><creator>Seabury, Jamison</creator><creator>Rosero, Spencer</creator><creator>Varma, Anika</creator><creator>Weinstein, Jennifer</creator><creator>Engebrecht, Charlotte</creator><creator>Dilek, Nuran</creator><creator>Heatwole, John</creator><creator>Alexandrou, Danae</creator><creator>Cohen, Brittany</creator><creator>Larkindale, Jane</creator><creator>Lynch, David R</creator><creator>Park, Courtney</creator><creator>Subramony, Sub H</creator><creator>Wagner, Ellen</creator><creator>Walther, Susan</creator><creator>Wells, McKenzie</creator><creator>Zizzi, Christine</creator><creator>Heatwole, Chad</creator><general>Lippincott Williams &amp; Wilkins</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7168-214X</orcidid><orcidid>https://orcid.org/0000-0002-8052-9240</orcidid></search><sort><creationdate>202310</creationdate><title>Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure</title><author>Seabury, Jamison ; Rosero, Spencer ; Varma, Anika ; Weinstein, Jennifer ; Engebrecht, Charlotte ; Dilek, Nuran ; Heatwole, John ; Alexandrou, Danae ; Cohen, Brittany ; Larkindale, Jane ; Lynch, David R ; Park, Courtney ; Subramony, Sub H ; Wagner, Ellen ; Walther, Susan ; Wells, McKenzie ; Zizzi, Christine ; Heatwole, Chad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c227t-c00aa4f05d88a258cbf52a0aa7f06ced5008822558ae3e7eb0b8c1d335c468d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seabury, Jamison</creatorcontrib><creatorcontrib>Rosero, Spencer</creatorcontrib><creatorcontrib>Varma, Anika</creatorcontrib><creatorcontrib>Weinstein, Jennifer</creatorcontrib><creatorcontrib>Engebrecht, Charlotte</creatorcontrib><creatorcontrib>Dilek, Nuran</creatorcontrib><creatorcontrib>Heatwole, John</creatorcontrib><creatorcontrib>Alexandrou, Danae</creatorcontrib><creatorcontrib>Cohen, Brittany</creatorcontrib><creatorcontrib>Larkindale, Jane</creatorcontrib><creatorcontrib>Lynch, David R</creatorcontrib><creatorcontrib>Park, Courtney</creatorcontrib><creatorcontrib>Subramony, Sub H</creatorcontrib><creatorcontrib>Wagner, Ellen</creatorcontrib><creatorcontrib>Walther, Susan</creatorcontrib><creatorcontrib>Wells, McKenzie</creatorcontrib><creatorcontrib>Zizzi, Christine</creatorcontrib><creatorcontrib>Heatwole, Chad</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurology. Clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seabury, Jamison</au><au>Rosero, Spencer</au><au>Varma, Anika</au><au>Weinstein, Jennifer</au><au>Engebrecht, Charlotte</au><au>Dilek, Nuran</au><au>Heatwole, John</au><au>Alexandrou, Danae</au><au>Cohen, Brittany</au><au>Larkindale, Jane</au><au>Lynch, David R</au><au>Park, Courtney</au><au>Subramony, Sub H</au><au>Wagner, Ellen</au><au>Walther, Susan</au><au>Wells, McKenzie</au><au>Zizzi, Christine</au><au>Heatwole, Chad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure</atitle><jtitle>Neurology. Clinical practice</jtitle><addtitle>Neurol Clin Pract</addtitle><date>2023-10</date><risdate>2023</risdate><volume>13</volume><issue>5</issue><spage>e200180</spage><pages>e200180-</pages><issn>2163-0402</issn><eissn>2163-0933</eissn><abstract>To develop a valid, disease-specific, patient-reported outcome (PRO) measure for adolescents and adults with Friedreich ataxia (FA) for use in therapeutic trials. We conducted semistructured qualitative interviews and a national cross-sectional study of individuals with FA to determine the most prevalent and burdensome symptoms and symptomatic themes to this population. These symptoms and symptomatic themes were included as questions in the first version of the Friedreich's Ataxia-Health Index (FA-HI). We subsequently used factor analysis, beta interviews with 17 individuals with FA, and test-retest reliability assessments with 20 individuals with FA to evaluate, refine, and optimize the FA-HI. Finally, we determined the capability of the FA-HI to differentiate between subgroups of FA participants with varying levels of disease severity. Participants with FA identified 18 symptomatic themes of importance to be included as subscales in the FA-HI. The FA-HI demonstrates high internal consistency and test-retest reliability, and it was identified by participants as highly relevant, comprehensive, and easy to complete. FA-HI total and subscale scores statistically differentiated between subgroups of participants with varying levels of disease burden. Initial evaluation of the FA-HI supports its validity and reliability as a PRO for assessing how individuals with FA feel and function.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>37646046</pmid><doi>10.1212/CPJ.0000000000200180</doi><orcidid>https://orcid.org/0000-0001-7168-214X</orcidid><orcidid>https://orcid.org/0000-0002-8052-9240</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2163-0402
ispartof Neurology. Clinical practice, 2023-10, Vol.13 (5), p.e200180
issn 2163-0402
2163-0933
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10462051
source Journals@Ovid Complete; PubMed Central; Alma/SFX Local Collection
title Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T23%3A17%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Friedreich's%20Ataxia-Health%20Index:%20Development%20and%20Validation%20of%20a%20Novel%20Disease-Specific%20Patient-Reported%20Outcome%20Measure&rft.jtitle=Neurology.%20Clinical%20practice&rft.au=Seabury,%20Jamison&rft.date=2023-10&rft.volume=13&rft.issue=5&rft.spage=e200180&rft.pages=e200180-&rft.issn=2163-0402&rft.eissn=2163-0933&rft_id=info:doi/10.1212/CPJ.0000000000200180&rft_dat=%3Cproquest_pubme%3E2858994115%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2858994115&rft_id=info:pmid/37646046&rfr_iscdi=true